ABL1 Kinase Domain Mutation Analysis
Methodology Molecular 
Test Name ABL1 Kinase Domain Mutation Analysis 
Test Description RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with imatinib resistance  
Clinical Significance Testing is recommended in CML with poor initial response to imatinib,  relapse, or progression to accelerated/blast phase.  Presence and identity of mutation may direct management to alternative drugs or stem cell transplant.   
Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
 
Storage and Transportation Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred. 
Turn around Time 10 days  
CPT Codes AMA 2013: 81401